D.A. Davidson & CO. Has $17.70 Million Holdings in Abbott Laboratories (NYSE:ABT)

D.A. Davidson & CO. decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 3.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 155,257 shares of the healthcare product maker's stock after selling 4,807 shares during the period. D.A. Davidson & CO.'s holdings in Abbott Laboratories were worth $17,701,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Insight Folios Inc boosted its stake in Abbott Laboratories by 3.3% during the third quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after buying an additional 87 shares during the period. Boltwood Capital Management grew its stake in shares of Abbott Laboratories by 0.4% during the third quarter. Boltwood Capital Management now owns 21,821 shares of the healthcare product maker's stock valued at $2,488,000 after buying an additional 89 shares during the last quarter. Wedge Capital Management L L P NC raised its holdings in shares of Abbott Laboratories by 2.9% in the third quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares during the period. Silicon Valley Capital Partners boosted its holdings in Abbott Laboratories by 8.7% during the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after acquiring an additional 89 shares during the period. Finally, Atwood & Palmer Inc. increased its stake in Abbott Laboratories by 6.5% in the third quarter. Atwood & Palmer Inc. now owns 1,478 shares of the healthcare product maker's stock worth $169,000 after purchasing an additional 90 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

ABT stock traded down $0.18 during trading on Tuesday, reaching $117.95. 4,033,021 shares of the company were exchanged, compared to its average volume of 5,684,780. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a market cap of $204.58 billion, a P/E ratio of 35.91, a PEG ratio of 2.77 and a beta of 0.72. The stock's 50 day moving average price is $115.59 and its 200 day moving average price is $110.04.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. Abbott Laboratories's revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. As a group, analysts predict that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Tuesday, October 15th. This represents a $2.20 annualized dividend and a yield of 1.87%. Abbott Laboratories's dividend payout ratio is presently 66.87%.

Analysts Set New Price Targets

A number of research firms have recently commented on ABT. Royal Bank of Canada upped their price target on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Morgan Stanley lifted their price target on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 17th. Jefferies Financial Group increased their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a research note on Thursday, October 17th. Piper Sandler increased their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, October 17th. Finally, Evercore ISI increased their target price on shares of Abbott Laboratories from $120.00 to $124.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $130.07.

Insider Buying and Selling at Abbott Laboratories

In related news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the completion of the sale, the chief executive officer now directly owns 220,059 shares of the company's stock, valued at $25,617,068.19. This represents a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is currently owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.